Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis

Would this help stroke survivors? We'll never know because we have NO stroke leaders or strategies.

Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis

1. Shu-Na Wang¹,
2. Tian-Ying Xu¹,
3. Wen-Lin Li² and
4. Chao-Yu Miao^1,3,*

Article first published online: 28 MAR 2016

DOI: 10.1111/cns.12539

© 2016 John Wiley & Sons Ltd

Issue

CNS Neuroscience & Therapeutics

Early View (Online Version of Record published before inclusion in an issue)

Additional Information(Show All)

How to CiteAuthor InformationPublication HistoryFunding Information

1. The first two authors contributed equally to this work.

Share|

• Abstract
• Article
• References
• Cited By

View Full Article (HTML) Enhanced Article (HTML) Get PDF (282K)

Keywords:

• Adult neurogenesis;
• Neurological disease;
• Nicotinamide adenine dinucleotide;
• Nicotinamide mononucleotide;
• Nicotinamide phosphoribosyltransferase

Summary

Adult neurogenesis is the process of generating new neurons throughout life in the olfactory bulb and hippocampus of most mammalian species, which is closely related to aging and disease. Nicotinamide phosphoribosyltransferase (NAMPT), also an adipokine known as visfatin, is the rate-limiting enzyme for mammalian nicotinamide adenine dinucleotide (NAD) salvage synthesis by generating nicotinamide mononucleotide (NMN) from nicotinamide. Recent findings from our laboratory and other laboratories have provided much evidence that NAMPT might serve as a therapeutic target to restore adult neurogenesis. NAMPT-mediated NAD biosynthesis in neural stem/progenitor cells is important for their proliferation, self-renewal, and formation of oligodendrocytes in vivo and in vitro. Therapeutic interventions by the administration of NMN, NAD, or recombinant NAMPT are effective for restoring adult neurogenesis in several neurological diseases. We summarize adult neurogenesis in aging, ischemic stroke, traumatic brain injury, and neurodegenerative disease and review the advances of targeting NAMPT in restoring neurogenesis. Specifically, we provide emphasis on the P7C3 family, a class of proneurogenic compounds that are potential NAMPT activators, which might shed light on future drug development in neurogenesis restoration.

View Full Article (HTML) Enhanced Article (HTML) Get PDF (282K)